China Pharma (NYSE:CPHI) Shares Down 1% – What’s Next?

China Pharma Holdings, Inc. (NYSE:CPHI) fell 1% during trading on Tuesday . The company traded as low as $0.5204 and last traded at $0.55. 12,815 shares were traded during trading, a decline of 79% from the average session volume of 60,485 shares. The stock had previously closed at $0.5554.

China Pharma Stock Down 1.0%

The company has a market capitalization of $2.76 million, a PE ratio of -0.96 and a beta of 1.17. The stock’s fifty day moving average is $1.00 and its two-hundred day moving average is $1.44. The company has a current ratio of 0.79, a quick ratio of 0.26 and a debt-to-equity ratio of 0.22.

Institutional Investors Weigh In On China Pharma

An institutional investor recently raised its position in China Pharma stock. Citadel Advisors LLC boosted its position in China Pharma Holdings, Inc. (NYSE:CPHI) by 31.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,426 shares of the company’s stock after purchasing an additional 7,356 shares during the period. Citadel Advisors LLC owned about 0.93% of China Pharma worth $59,000 as of its most recent SEC filing.

China Pharma Company Profile

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.